

Curdin Conrad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615364/publications.pdf>

Version: 2024-02-01

80
papers

7,917
citations

109137

35
h-index

66788

78
g-index

86
all docs

86
docs citations

86
times ranked

10091
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNAâ€“Peptide Complexes in Systemic Lupus Erythematosus. <i>Science Translational Medicine</i> , 2011, 3, 73ra19.	5.8	1,080
2	Plasmacytoid predendritic cells initiate psoriasis through interferon-Î± production. <i>Journal of Experimental Medicine</i> , 2005, 202, 135-143.	4.2	999
3	Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-Î±. <i>Journal of Experimental Medicine</i> , 2004, 199, 731-736.	4.2	463
4	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nature Communications</i> , 2014, 5, 5621.	5.8	427
5	Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors. <i>Archives of Dermatology</i> , 2004, 140, 1490-5.	1.7	364
6	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. <i>Nature Medicine</i> , 2005, 11, 138-145.	15.2	356
7	Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. <i>Journal of Experimental Medicine</i> , 2010, 207, 2921-2930.	4.2	292
8	The cGASâ€“STING pathway drives type I IFN immunopathology in COVID-19. <i>Nature</i> , 2022, 603, 145-151.	13.7	272
9	Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells. <i>Cancer Research</i> , 2012, 72, 5240-5249.	0.4	267
10	Î±1Î²1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. <i>Nature Medicine</i> , 2007, 13, 836-842.	15.2	241
11	Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. <i>Journal of Immunology</i> , 2010, 185, 5688-5691.	0.4	207
12	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. <i>Nature Communications</i> , 2018, 9, 25.	5.8	194
13	Dendritic-cell-based therapeutic vaccination against cancer. <i>Current Opinion in Immunology</i> , 2005, 17, 163-169.	2.4	182
14	TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. <i>Nature Immunology</i> , 2015, 16, 970-979.	7.0	182
15	Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1143-1153.	3.0	173
16	Psoriasis: from Pathogenesis to Targeted Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 102-113.	2.9	151
17	Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to selfâ€“DNA. <i>European Journal of Immunology</i> , 2015, 45, 203-213.	1.6	129
18	The pathogenic role of tissue-resident immune cells in psoriasis. <i>Trends in Immunology</i> , 2007, 28, 51-57.	2.9	128

#	ARTICLE	IF	CITATIONS
19	Targeting CD8+ T cells prevents psoriasis development. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 274-276.e6.	1.5	125
20	Interleukin 23 as a Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. <i>JAMA Dermatology</i> , 2017, 153, 304.	2.0	111
21	Diversification of human plasmacytoid dendritic cells in response to a single stimulus. <i>Nature Immunology</i> , 2018, 19, 63-75.	7.0	106
22	Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. <i>Frontiers in Immunology</i> , 2018, 9, 2746.	2.2	96
23	Interplay between keratinocytes and immune cells – Recent insights into psoriasis pathogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 963-968.	1.2	92
24	The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin. <i>Nature Immunology</i> , 2020, 21, 1034-1045.	7.0	90
25	Human $\alpha\text{T}^{\text{H}}9$ cells are a subpopulation of PPAR- γ^3 T _H 2 cells. <i>Science Immunology</i> , 2019, 4, .	5.6	75
26	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	3.3	65
27	Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. <i>Seminars in Immunology</i> , 2009, 21, 101-109.	2.7	56
28	PASS Syndrome: An IL-1-Driven Autoinflammatory Disease. <i>Dermatology</i> , 2016, 232, 254-258.	0.9	51
29	The IL-12 Family Member p40 Chain as a Master Switch and Novel Therapeutic Target in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2004, 123, xiv-xv.	0.3	49
30	Pyoderma gangrenosum. <i>Pyoderma gangraenosum. JDDG - Journal of the German Society of Dermatology</i> , 2005, 3, 334-342.	0.4	49
31	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , 2018, 25, 3564-3572.e4.	2.9	49
32	Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. <i>British Journal of Dermatology</i> , 2005, 152, 1211-1218.	1.4	46
33	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1732-1742.e17.	0.3	42
34	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , 2019, 3, 3674-3687.	2.5	40
35	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406.	0.9	39
36	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	0.6	39

#	ARTICLE	IF	CITATIONS
37	Melanoma and innate immunity â€œ Active inflammation or just erroneous attraction?. Seminars in Cancer Biology, 2009, 19, 84-91.	4.3	35
38	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	0.9	32
39	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. British Journal of Dermatology, 2022, 186, 773-781.	1.4	32
40	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and Therapy, 2020, 10, 663-670.	1.4	28
41	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. International Journal of Molecular Sciences, 2020, 21, 5102.	1.8	26
42	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 123-134.	1.3	25
43	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment, 2020, 31, 476-483.	1.1	23
44	Biomarkers of disease progression in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 481-493.	1.4	22
45	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. British Journal of Dermatology, 2021, 185, 1160-1168.	1.4	21
46	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. Journal of Dermatological Treatment, 2022, 33, 1652-1660.	1.1	20
47	Trauma as Triggering Factor for Development of Melanocytic Nevi. Dermatology, 2010, 220, 291-296.	0.9	18
48	Type I IFNs at the Interface between Cutaneous Immunity and Epidermal Remodeling. Journal of Investigative Dermatology, 2012, 132, 1759-1762.	0.3	18
49	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology, 2016, 232, 655-663.	0.9	18
50	Animal models of psoriasis and psoriatic arthritis: An update. Current Rheumatology Reports, 2006, 8, 342-347.	2.1	17
51	Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment. Oncolmmunology, 2013, 2, e23887.	2.1	17
52	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology, 2021, 237, 166-178.	0.9	17
53	Mechanisms of psoriasis. Drug Discovery Today Disease Mechanisms, 2004, 1, 315-319.	0.8	16
54	Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy. Skin Pharmacology and Physiology, 2006, 19, 124-131.	1.1	16

#	ARTICLE	IF	CITATIONS
55	Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021—a two-round Delphi survey among international experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1467-1476.	1.3	14
56	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 494-506.	1.4	14
57	The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. <i>Dermatology</i> , 2015, 230, 75-81.	0.9	13
58	Efficacy and safety of <sc>TNF</sc> blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2330-2338.	1.3	13
59	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
60	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1650.	1.8	11
61	Dendritic cell-based cancer therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2003, 5, 405-12.	2.8	11
62	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1578-1583.	1.3	11
63	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 403-412.	1.3	10
64	Anti-TNF Therapy in the Treatment of Psoriasis in a Patient with Acute-on-Chronic Pancreatitis. <i>Dermatology</i> , 2013, 227, 193-196.	0.9	9
65	New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. <i>Antibodies</i> , 2021, 10, 12.	1.2	8
66	Xenotransplantation Model of Psoriasis. <i>Methods in Molecular Biology</i> , 2017, 1559, 83-90.	0.4	7
67	Baricitinib-induced paradoxical psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e391-e393.	1.3	6
68	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2022, 12, 81-95.	1.4	6
69	Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the <sc>SERENA</sc> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1796-1804.	1.3	6
70	Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. <i>Psoriasis: Targets and Therapy</i> , 2013, , 1.	1.2	5
71	Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. <i>British Journal of Dermatology</i> , 2021, 185, 865-867.	1.4	5
72	Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 675-683.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Papillon-Delefevre syndrome treated by acitretin: case report and cytokine profile. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	4
74	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. Dermatology and Therapy, 2022, 12, 233-241.	1.4	4
75	Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab. Journal of the American Academy of Dermatology, 2020, 83, 261-263.	0.6	3
76	TYK-ing all the boxes in psoriasis. Journal of Allergy and Clinical Immunology, 2022, 149, 1936-1939.	1.5	3
77	Purpura of the Face and Neck: An Atypical Clinical Presentation Revealing a Hepatosplenic T Cell Lymphoma. Case Reports in Dermatology, 2014, 6, 37-42.	0.3	2
78	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	1.3	2
79	Psoriasis, Cutaneous Lupus Erythematosus and Immunobiology of the Skin. , 2016, , 192-203.		0
80	Infections Associated with Immunobiologics. , 2017, , 796-804.e2.		0